Status:
TERMINATED
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
Lead Sponsor:
Antisoma Research
Conditions:
Breast Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to compare the overall tumour response rate per RECIST in postmenopausal women with metastatic or locally advanced breast cancer receiving AS1402 in combination with letrozole...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed locally advanced or metastatic breast cancer not amenable to curative therapy
- Measurable disease according to the RECIST criteria
- Documented estrogen receptor-positive and/or progesterone receptor-positive tumour
- Postmenopausal women
Exclusion
- Prior chemotherapy and/or endocrine therapy for advanced breast disease
- Relapse within 12 months after treatment discontinuation of an aromatase inhibitor in the adjuvant setting
- Unknown hormonal receptor status
- Known HER2/neu-positivity
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2011
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00770354
Start Date
September 1 2008
End Date
August 1 2011
Last Update
August 10 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
State Medical Institution
Pyatigorsk, Stavropol Kray, Russia, 357500
2
State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncological Center
Chelyabinsk, Russia, 454087